Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review

被引：36
|
作者：
Camus, Baptiste [1 ,2 ]
Cottereau, Anne-Segolene [2 ,3 ]
Palmieri, Lola-Jade [1 ,2 ]
Dermine, Solene [1 ,2 ]
Tenenbaum, Florence [3 ]
Brezault, Catherine [1 ,2 ]
Coriat, Romain [1 ,2 ]
机构：
[1] Cochin Hosp, AP HP Ctr, Gastroenterol & Digest Oncol Unit, 27 Rue Faubourg St Jacques, F-75014 Paris, France
[2] Univ Paris, Fac Med, F-75006 Paris, France
[3] Cochin Hosp, AP HP Ctr, Dept Nucl Med, 27 Rue Faubourg St Jacques, F-75014 Paris, France
来源：
JOURNAL OF CLINICAL MEDICINE | 2021年 / 10卷 / 06期
关键词：
neuroendocrine tumors; neoplasm metastasis; PRRT; peptide receptor radionuclide therapy; gastroenteropancreatic tumor; pulmonary tumor; RADIOLABELED SOMATOSTATIN ANALOG; TYR(3) OCTREOTATE; LU-177-DOTATATE; EFFICACY; LU-177-OCTREOTATE; FEASIBILITY; TOXICITY; SURVIVAL; NEN; G3;
D O I：
10.3390/jcm10061267
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Radionuclide therapy for neuroendocrine tumors is a form of systemic radiotherapy that allows the administration of targeted radionuclides into tumor cells that express a large quantity of somatostatin receptors. The two most commonly used radio-peptides for radionuclide therapy in neuroendocrine tumors are Y-90-DOTATOC and Lu-177-DOTATATE. Radio-peptides have been used for several years in the treatment of advanced neuroendocrine tumors. Recently, the randomized Phase III study NETTER-1 compared(177)Lu-DOTATATE versus high-dose (double-dose) octreotide LAR in patients with metastatic midgut neuroendocrine tumors, and demonstrated its efficacy in this setting. Strong signals in favor of efficiency seem to exist for other tumors, in particular for pancreatic and pulmonary neuroendocrine tumors. This focus on radionuclide therapy in gastroenteropancreatic and pulmonary neuroendocrine tumors addresses the treatment modalities, the validated and potential indications, and the safety of the therapy.
引用
收藏
页码：1 / 18
页数：15
相关论文
共 50 条
  • [31] Peptide receptor radionuclide therapy of neuroendocrine tumors
    Haug, A. R.
    Bartenstein, P.
    ONKOLOGE, 2011, 17 (07): : 602 - +
  • [32] Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors
    Bodei, Lisa
    Kidd, Mark
    Prasad, Vikas
    Modlin, Irvin M.
    NEUROENDOCRINE TUMORS: A MULTIDISCIPLINARY APPROACH, 2015, 44 : 198 - 215
  • [33] Can tumor absorbed dose predict response to Peptide Receptor Radionuclide Therapy (PRRT) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)?
    Mileva, M.
    Marin, G.
    Levillain, H.
    van Bogaert, C.
    Critchi, G.
    Marin, C.
    Flamen, P.
    Karfis, I
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 153 - 153
  • [34] Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors
    Basu, Sandip
    Parghane, Rahul, V
    Kamaldeep
    Chakrabarty, Sudipta
    SEMINARS IN NUCLEAR MEDICINE, 2020, 50 (05) : 447 - 464
  • [35] Surgery enhances the effectiveness of peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumors Discussion
    Demeure, Michael
    Tobias, Joseph
    Dickson, Paxton
    Howe, Jim
    Beck, Timothy
    SURGERY, 2025, 177
  • [36] The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future
    Liberini, Virginia
    Huellner, Martin W.
    Grimaldi, Serena
    Finessi, Monica
    Thuillier, Philippe
    Muni, Alfredo
    Pellerito, Riccardo E.
    Papotti, Mauro G.
    Piovesan, Alessandro
    Arvat, Emanuela
    Deandreis, Desiree
    DIAGNOSTICS, 2020, 10 (12)
  • [37] Reduced efficacy of repeated peptide receptor radionuclide therapy (PRRT) in progressive gastroenteropancreatic neuroendocrine tumours (GEP-NET)?
    Schnurr, J.
    Reimold, M.
    Dittmann, H.
    Kupferschlaeger, J.
    Bares, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S396 - S396
  • [38] Peptide Receptor Radionuclide Therapy (PRRT) a Novel Option as Neoadjuvant Therapy for Pancreatic Neuroendocrine Tumors: A Surgical Series
    Miotto, M.
    Nessi, C.
    Cingarlini, S.
    Severi, S.
    Paganelli, G.
    Malleo, G.
    D'Onofrio, M.
    Pea, A.
    Vincenzi, S.
    Scarpa, A.
    Salvia, R.
    Landoni, L.
    NEUROENDOCRINOLOGY, 2019, 108 : 254 - 254
  • [39] Utility of Midpoint Imaging in Patients Receiving Peptide Receptor Radionuclide Therapy (PRRT) for Advance Progressive Gastroenteropancreatic-Neuroendocrine Tumors (GEP-NETs)
    Norman, Aurora P.
    Wee, Christopher
    Hobday, Timothy J.
    Kendi, Ayse T.
    Johnson, Geoffrey B.
    Thorpe, Matthew P.
    Lunn, Brendan W.
    Bach, Corrie R.
    Halfdanarson, Thorvardur R.
    PANCREAS, 2022, 51 (03) : E45 - E45
  • [40] Systemic inflammatory index (SII) in neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT)
    Teran Brage, E.
    Campana-Diaz, E.
    Navarro Martin, M.
    Garcia-Talavera, P.
    Lopez Gutierrez, A.
    Reguera Puertas, P.
    Rama-Alonso, S.
    Roldan Ruiz, J.
    Posado Dominguez, L.
    Pablo Martin, E.
    Lozano Mejorada, R.
    Fonseca Sanchez, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S95 - S95
12345